UHP Awaits FDA Response on Clinical Trial Violations and IDE Approval
United Health Products updates on FDA discussions for CelluSTAT Hemostatic Gauze approval, aiming to revolutionize surgical bleeding control with natural solutions.
The resolution of UHP's FDA Warning Letter and the approval of its IDE are critical steps toward bringing CelluSTAT Hemostatic Gauze to the human surgical market. This development is significant for healthcare providers and patients seeking innovative, natural solutions for bleeding control, potentially improving surgical outcomes and patient care.
